2026 Akero Therapeutics, Inc.
Cardiometabolic Therapeutics
2open roles
$45.5Mlatest round · Venture round · Dec 2018 · 7 yr ago
3backers · Apple Tree Partners, Atlas Venture
50+team · employees, estimated range
Overview
Akero Therapeutics is a clinical-stage company developing transformational therapies for people with metabolic dysfunction-associated steatohepatitis (MASH).
Key facts
As of Nov 13, 2026, Alion lists 2 open roles at 2026 Akero Therapeutics, Inc. 2026 Akero Therapeutics, Inc. is headquartered in South San Francisco, United States. It was founded in 2017. The latest round is Venture - Series Unknown of $45.5M, announced in 2018.
- Open roles
- 2Its careers board, read on Nov 12, 2026
- Headquarters
- South San Francisco, United StatesAlion company profile, updated Nov 12, 2026
- Founded
- 2017Alion company profile, updated Nov 12, 2026
- Employees
- 50+Alion company profile, an estimated range
- Total raised
- $45.5MSum of 1 equity round Alion knows
- Latest round
- Venture - Series Unknown · $45.5M · Dec 10, 2018SEC Form D filing · sec.gov
Official records
Funding and backers
Total raised
$45.5M
1 round on record
Latest round
$45.5M
Venture round · Dec 2018 · 7 yr ago
Team
51-200
employees, estimated range
Hiring now
2
+2 posted in 30 days
Backers
3
Apple Tree Partners, Atlas Venture
The money's age
Long since its last round
95 months since the last round · and hiring
Momentum
27/100
hiring for its size
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Dec 2018 | $45.5M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Akero Therapeutics, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Andrew ChengExecutive Officer, DirectorSEC Form D
Jonathan YoungExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Apple Tree Partners 
Atlas Venture 
venBio Partners Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Diasome’s HDV™ platform redefines drug delivery by targeting the liver, improving treatment for diabetes, obesity, and metabolic…
Kailera is a late clinical-stage biotechnology company advancing a diversified pipeline of GLP-1 therapies to provide options for people…
Refoxy Pharmaceuticals GmbH is a pre-clinical biotech company developing FOXO3-targeting therapies to restore cellular balance and treat…
PAhR Therapeutics is a clinical-stage biotech company advancing innovative therapies to treat pulmonary arterial hypertension (PAH) through…
NeuTigers turns existing consumer wearables into a privacy-preserving metabolic intelligence platform, backed by proprietary Edge-AI and…
Ilant provides comprehensive, employer-backed metabolic care. Drive meaningful health outcomes with expert clinical guidance, care teams…
Jobs
$153k – $267k per year · Remote (United States) · 8+ years exp
GCP
Life Sciences
Good Clinical Practice
Apply
$153k – $267k per year · Remote (United States) · 8+ years exp
GCP
Life Sciences
Good Clinical Practice
Apply
Salary insights
Compensation ranges based on this company's open jobs
Median
$267k
Typical range
$267k
Open positions
2
2
Jobs
Staff
100%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Staff | 2 | $267k | $267k |
Highest paying role
Clinical Program Manager - Global Study Lead
$267k
Normalized to USD per year
Visa sponsorship
0
H-1B filings in 12 months
2
Open roles in United States
In the register as Akero Therapeutics, Inc., South San Francisco, CA
Other sponsors in the same field
Eli Lilly and Company 420 filings
Amgen 372 filings
Bristol Myers Squibb 218 filings
Novo Nordisk 39 filings
See 2 open roles Alert me
US Department of Labor · latest filing Jul 1, 2024 · Visa details by country
Growth
Hiring Momentum
30/100
Slowing
Open positions
2
0 opened / 0 closed in 30 days
Median time-to-fill
14 days
faster than 69% of the market
ATS activity
Every ~6 hours
11/12/2026
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Management
67% ▲
Early Careers
33% ▲
Financials
Total raised
$45.5M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2018 | $45.5M | Details |
People
Andrew Cheng
Executive Officer, Director
Jonathan Young
Executive Officer
Kevin Bitterman
Director
Mark Iwicki
Director
Aaron Kantoff
Director
Aaron Royston
Director
Graham Walmsley
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Tech stack
Technologies named in job postings at 2026 Akero Therapeutics, Inc. over the last 12 months, by layer, with the share of postings for each.
Technologies in use
2
Postings analysed
2
Stack modernity
53/100
Cloud & platforms
GCP
Practices & domains
Good Clinical Practice
Sign in to see how your skills match this stack
Sign In
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
Investor highlights - Get an overview of our investor services
Here you will get an overview of all the information and services that we provide for you as a Novo Nordisk investors.
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
South San Francisco
United States
HQ
601 Gateway Boulevard Suite 350 South San Francisco, CA 94080
50-200 est. staff
601 Gateway Boulevard Suite 350 South San Francisco, CA 94080
How to cite this page
Alion, "2026 Akero Therapeutics, Inc.: key facts", as of Nov 13, 2026. https://alion.io/company/akerotx
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0